Business Context and Reporting Period
Matinas Biopharma Holdings, Inc. (MTNB) filed a Form 8-K on August 31, 2026, regarding its listing status on the NYSE American. The company is incorporated in Delaware and operates from Bedminster, New Jersey.
Key Financial Metrics
- Stockholders' Equity: $1.8 million as of June 30, 2026.
- Profitability: The company reported losses from continuing operations and/or net losses in its five most recent fiscal years.
- Revenue, Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for revenue, operating cash flow, debt levels, or liquidity ratios beyond the stockholders' equity figure.
Material Changes and Listing Status
The company received written notice from the NYSE American on August 31, 2026, stating it is not in compliance with Section 1003(a)(i) of the Company Guide. This standard requires a minimum of $2.0 million in stockholders' equity for companies with losses in two of their three most recent fiscal years. The company's equity of $1.8 million falls below this threshold.
This notice follows previous non-compliance notices regarding Sections 1003(a)(ii) and 1003(a)(iii) issued in April and June 2026. The company's common stock will continue to trade under the symbol "MTNB" with a ".BC" indicator denoting non-compliance.
Guidance, Outlook, and Risks
- Compliance Plan: The company submitted a plan on May 4, 2026, which was accepted by the NYSE American. The company has been granted a plan period through October 2, 2027, to regain compliance.
- Delisting Risk: If the company fails to meet all stockholders' equity standards by the October 2, 2027 deadline, or fails to make progress consistent with the plan, the NYSE American will initiate delisting proceedings.
- Operational Impact: The notice has no immediate impact on ongoing business operations or SEC reporting requirements.
- Forward-Looking Statements: The filing includes standard disclaimers regarding uncertainties in regaining compliance and future business performance.
Investor Verification Checklist
- Verify the company's current stockholders' equity against the $2.0 million threshold required for continued listing.
- Monitor the company's progress toward the October 2, 2027 compliance deadline.
- Review the specific actions outlined in the May 4, 2026 plan to regain compliance.
- Check for any updates regarding the ".BC" trading indicator status.
- Assess the risk of potential delisting if equity targets are not met by the plan period deadline.